logo inner

Senior Scientist I/II - Epigenetic Editing Technologies

Mammoth BiosciencesMammoth Brisbane, California, United StatesOnsite
This job is no longer open
OPPORTUNITY
Mammoth is hiring a Senior Scientist I/II to contribute to R&D projects within the Editing Technologies team. The Editing Technologies team develops next-generation CRISPR tools for therapeutic genome editing applications, with scope spanning from technological ideation to translational proof-of-concept. The successful candidate will take a lead role as an individual contributor in designing novel epigenetic editing tools and developing experimental assays and workflows to evaluate their efficacy.

Strength in wet lab execution and experimental design along with deep scientific understanding of epigenetics and epigenetic editing will be critical to the role. The candidate will work within a core team of epigenetic tool developers and collaborate cross-functionally with a diverse technical staff with expertise in disease biology, bioinformatics, protein engineering, high-throughput screening/automation, reagent production, and in vivo evaluation. This is a fantastic opportunity to impact human health by making CRISPR tools that cure genetic disease.

KEY RESPONSIBILITIES


  • Contribute creatively to the design of new epigenetic editing tools through ideation and literature review
  • Develop scalable assays for measuring gene and protein expression, epigenetic state, and/or cellular phenotype
  • Plan, design and execute experiments for CRISPR tool evaluation
  • Provide instruction to junior team members
  • Document experiments in electronic laboratory notebooks and present results at internal meetings
  • Disclose inventions to the IP team for patenting
  • Other duties as assigned

REQUIRED QUALIFICATIONS


  • PhD in Molecular Biology, Cell Biology, Bioengineering or a related discipline; 3+ years of relevant professional experience in industry or academia, following completion of PhD. For non-PhD candidates with a Bachelor's degree, 8+ years of professional experience is required 
  • 2+ years of hands-on experience designing and refining fusion proteins for CRISPR or other DNA binding proteins (ZNF, TALE)
  • 2+ years of hands-on experience designing, executing, and analyzing CRISPRa/i or epigenetic editing experiments in mammalian cells
  • 3+ years hands-on experience in at least two of the following areas: 
  • Epigenetic characterization assays including bisulfite sequencing (targeted or whole genome), EM-seq, ChIP-qPCR, and/or ChIP-seq
  • b. Flow cytometry and/or fluorescence-activated cell sorting (FACS)
  • c. Transcript/protein quantification assays including RT-qPCR; d/ddPCR, RNA-seq, ELISA, and/or MSD
  • d. Automated methods for high-throughput molecular/cell biology workflows

PREFERRED QUALIFICATIONS


  • 2+ years experience with mammalian cell line engineering
  • 2+ years experience with developing pooled screening approaches for high-throughput tool evaluation
  • 1+ years experience working with disease-specific cell models and optimizing nucleic acid delivery via lipofection, nucleofection, and/or viral transduction
  • 1+ years experience managing direct reports
  • Working proficiency with common bioinformatics tools (Benchling, JMP, SQL, R, Python)

BENEFITS


  • Company-paid health/vision/dental benefits
  • Unlimited vacation and generous sick time
  • Company-sponsored meals and snacks
  • Wellness, caregiver and ergonomics benefits
  • 401(k) with company matching

Base Salary Range: $ 150,000 - $182,350Actual base salary will be determined by relevant professional experience, applicable skills, and internal equity. COMPANYMammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing.

The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law.

This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law. Apply for this job

This job is no longer open

Life at Mammoth Biosciences

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13 and Cas14, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
Thrive Here & What We Value- Unlimited vacation and generous sick time- Company-sponsored meals and snacks- Wellness, caregiver, and ergonomics benefits- 401(k) with company matching- Equal opportunity policy
Your tracker settings

We use cookies and similar methods to recognize visitors and remember their preferences. We also use them to measure ad campaign effectiveness, target ads and analyze site traffic. To learn more about these methods, including how to disable them, view our Cookie Policy or Privacy Policy.

By tapping `Accept`, you consent to the use of these methods by us and third parties. You can always change your tracker preferences by visiting our Cookie Policy.

logo innerThatStartupJob
Discover the best startup and their job positions, all in one place.
Copyright © 2024